Evidence map›Paper›PMID 29184071›Full record

ArticleScientific reports2017

Preventive Trichuris suis ova (TSO) treatment protects immunocompetent rabbits from DSS colitis but may be detrimental under conditions of immunosuppression.

Irina Leonardi, Alexandra Gerstgrasser, Thomas S B Schmidt, Flora Nicholls, Bernhard Tewes, Roland Greinwald, Christian von Mering, Gerhard Rogler, Isabelle Frey-Wagner

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Frontiers in immunology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Integrative medicine research · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Safety of viable embryonated eggs of the whipwormEFSA journal. European Food Safety Authority · 2019
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Irina LeonardiDivision of Gastroenterology and Hepatology USZ, Zurich, Switzerland.
Alexandra GerstgrasserDivision of Gastroenterology and Hepatology USZ, Zurich, Switzerland.
Thomas S B SchmidtInstitute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-8587-4177
Flora NichollsCentral Biological Laboratory, USZ, Zurich, Switzerland.
Bernhard TewesResearch and Development, Dr. Falk Pharma GmbH, Freiburg, Germany.
Roland GreinwaldResearch and Development, Dr. Falk Pharma GmbH, Freiburg, Germany.
Christian von MeringInstitute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-7734-9102
Gerhard RoglerDivision of Gastroenterology and Hepatology USZ, Zurich, Switzerland.
Isabelle Frey-WagnerDivision of Gastroenterology and Hepatology USZ, Zurich, Switzerland. isabelle.frey@usz.ch.ORCID 0000-0002-0125-3072
Dr Falk Pharma (Germany) · DEUniversity of Zurich · CHCornell University · USImmunologie-Zentrum Zürich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trichuris suis ova (TSO) have been tested for therapeutic application in inflammatory bowel diseases (IBD) yet understanding of the underlying mechanisms and safety in an immunocompromised host is limited due to lack of a suitable animal model. We used a recently established rabbit model of dextran sodium sulphate (DSS) induced colitis to study the efficacy, mechanisms and safety of TSO therapy in immunocompetent and immunosuppressed animals. TSO treatment prevented the DSS induced weight loss, delayed the onset of DSS induced symptoms by 2 days and significantly reduced the disease activity (DAI). TSO treatment protected caecal histology and prevented the colitis-associated loss in faecal microbiota diversity. Mainly the transcriptome of lamina propria mononuclear cells (LPMC) was affected by TSO treatment, showing dampened innate and adaptive inflammatory responses. The protective effect of TSO was lost in immunosuppressed rabbits, where TSO exacerbated colitis. Our data show that preventive TSO treatment ameliorates colitis severity in immunocompetent rabbits, modulates LPMC immune responses and reduces faecal dysbiosis. In contrast, the same TSO treatment exacerbates colitis in immunosuppressed animals. Our data provide further evidence for a therapeutic effect of TSO in IBD, yet caution is required with regard to TSO treatment in immunosuppressed patients.

Indexed as

Biological TherapyImmunosuppression TherapyAnimalsColitisDextran SulfateDisease Models, AnimalGastrointestinal MicrobiomeGene Expression ProfilingHumansImmunocompromised HostInflammatory Bowel DiseasesIntestinal MucosaMacrophagesRabbitsTranscriptomeTrichurisDextran Sulfate

Identifiers

PMID29184071
PMCPMC5705695
OpenAlexW2769724053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.